|1.||Okuno, S: 4 articles (03/2001 - 06/2000)|
|2.||Harada, M: 4 articles (03/2001 - 06/2000)|
|3.||Suzuki, T: 3 articles (03/2001 - 12/2000)|
|4.||Kawaguchi, Takayuki: 2 articles (12/2011 - 02/2005)|
|5.||Okuno, Satoshi: 2 articles (12/2011 - 02/2005)|
|6.||Crea, Attilio: 2 articles (11/2008 - 11/2006)|
|7.||Sakamura, Y: 2 articles (03/2001 - 06/2000)|
|8.||Sakakibara, H: 2 articles (03/2001 - 12/2000)|
|9.||Yano, T: 2 articles (12/2000 - 06/2000)|
|10.||Imai, J: 2 articles (12/2000 - 06/2000)|
06/01/2000 - "The significant increases in the amount and exposure time of released T-2513 in the tumor explain well the enhanced efficacy of T-0128. "
03/12/2001 - "Overall, our data provide a rationale for the selection of the carrier for T-0128 and a need for pharmacokinetic studies to evaluate the influences of tumor on the drug disposition."
03/12/2001 - "This study examines the effects of carrier, dose, and tumor on T-0128 pharmacokinetics. "
06/01/2000 - "Pharmacokinetic studies were performed to correlate the efficacy results obtained for T-0128 with plasma and tissue drug concentrations using Walker-256 tumor-bearing rats. "
03/12/2001 - "The presence of tumor reduced the plasma half-life and systemic exposure of T-0128. "
06/01/2000 - "The in vivo antitumor study against Walker-256 carcinoma demonstrated that T-0128 was 10 times as active as T-2513, supporting this concept. "
06/01/2000 - "T-0128 at 10 mg/kg weekly for 3 weeks (one-tenth of its MTD) cured LX-1 lung carcinoma. "
02/15/2005 - "and maintained in nude mice, and characterized the pharmacokinetic profile of MEN4901/T-0128 in nude mice bearing human gastric carcinoma St-4. "
06/01/2000 - "Even a single i.v. injection of T-0128 at 6 mg/kg (based on the amount of T-2513 bound to CM dextran) induced complete regression of MX-1 mammary carcinoma. "
02/15/2005 - "MEN4901/T-0128 administered i.v. showed a marked antitumor activity in each of these tumor models, producing tumor shrinkage in the models of H-204 and H-181 carcinomas at its maximum tolerated dose of 80 mg/kg (expressed as T-2513) weekly for 4 weeks (q7d x 4) and tumor-shrinking or marked growth-inhibitory effects in the models of H-81, H-110, Mqnu-1, H-74, and H-48 carcinomas at 1/3 of its maximum tolerated dose (q7d x 4). "
|3.||Colorectal Neoplasms (Colorectal Cancer)
|4.||Neoplasm Metastasis (Metastasis)
12/01/2011 - "At the most efficacious dose of MEN4901/T-0128, only 1 of 12 animals had lymph node metastasis compared with 19 of 20 in the control group. "
12/01/2011 - "MEN4901/T-0128, with treatment beginning on d 49 after SOI, was highly effective on lymph node metastasis as well as against the primary tumor. "
|5.||Colonic Neoplasms (Colon Cancer)
|3.||K 76 carboxylic acid
|4.||Dihydrotachysterol (AT 10)
|10.||Myristic Acid (Tetradecanoic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)